Hinova PharmaceuticalsSHSE:688302 +2.03%26 Gross Margin % is 99.82% as of Mar. 2026, which is 9% above its 10-year median of 91.55. GuruFocus rates SHSE:688302 with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 732 Biotechnology companies, Hinova Pharmaceuticals ranks better than 97.4% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Hinova Pharmaceuticals had a gross margin of 99.82% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Hinova Pharmaceuticals Gross Margin % Related Terms
Hinova Pharmaceuticals Gross Margin % Historical Data
* Premium members only.
The historical data trend for Hinova Pharmaceuticals's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688302 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Hinova Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hinova Pharmaceuticals Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hinova Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Hinova Pharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Hinova Pharmaceuticals (SHSE:688302) has a Gross Margin % of 99.82% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Hinova Pharmaceuticals and its competitors. This is near median its historical median of 91.55. Over the past decade, Hinova Pharmaceuticals' Gross Margin % has ranged from 8.45 to 99.29. According to the industry distribution chart, Hinova Pharmaceuticals ranks #19 out of 732 companies in the Biotechnology industry, placing it in the top 2.6%.
Is Hinova Pharmaceuticals' Gross Margin % too high?
Hinova Pharmaceuticals' current Gross Margin % of 99.82% is near median its 10-year median of 91.55. Over the past 10 years, this metric has ranged from a low of 8.45 to a high of 99.29. The Biotechnology industry median Gross Margin % is 60.91. Hinova Pharmaceuticals' value of 99.82% is 63.9% above this industry median. Based on the distribution chart, Hinova Pharmaceuticals ranks #19 out of 732 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Hinova Pharmaceuticals has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Hinova Pharmaceuticals' Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hinova Pharmaceuticals ranks #19 out of 732 companies for Gross Margin %. This places Hinova Pharmaceuticals in the top 3% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.91. Hinova Pharmaceuticals' value of 99.82% is 63.9% above this benchmark. Historically, Hinova Pharmaceuticals' own Gross Margin % has ranged from 8.45 to 99.29 over the past decade. While the company's 10-year median is 91.55 vs. the industry median of 60.91, Hinova Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hinova Pharmaceuticals's current Gross Margin % of 99.82% is 63.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Hinova Pharmaceuticals and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hinova Pharmaceuticals's current Gross Margin % is 99.82%, which is near median its own 10-year median of 91.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hinova Pharmaceuticals stock overvalued right now?
Hinova Pharmaceuticals (SHSE:688302) has a current Gross Margin % of 99.82%. The current Gross Margin % is 99.82%, which is near median its 10-year median of 91.55 and 63.9% above the Biotechnology industry median of 60.91. Hinova Pharmaceuticals' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Hinova Pharmaceuticals (SHSE:688302), the current Gross Margin % is 99.82% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hinova Pharmaceuticals Inc is an international drug company based on technology platforms such as deuterium and PROTAC, aiming to develop Best-in-class and First-in-class drugs with major clinical needs. The company focuses on the research and development of drugs in therapeutic areas such as oncology and metabolic diseases, focusing on providing safe, effective and affordable drugs for patients, and is committed to the development and production of drugs with global rights and interests.
26GF Score
Get the complete analysis for SHSE:688302
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688302 has been successfully added to your 
